Bill > SB2539

This bill amends the Illinois Controlled Substances Act to require prescribers to offer a prescription for naloxone hydrochloride or another similar FDA-approved drug to patients under certain circumstances, such as when the patient is prescribed a high dose of opioids or concurrently prescribed opioids and benzodiazepines. The bill also requires prescribers to provide education to patients and their designated representatives on overdose prevention and the use of these reversal drugs. Prescribers who do not comply with these requirements will be subject to disciplinary action, but the bill does not create a private right of action against prescribers or limit their liability for negligence. The bill's provisions do not apply to patients receiving hospice care. The bill is intended to address the opioid crisis in Illinois, which has been exacerbated by the COVID-19 pandemic, and to address long-standing health inequities in opioid-related outcomes.

https://www.ilga.gov/legislation/BillStatus.asp?DocNum=2539&GAID=16&DocTypeID=SB&SessionID=110&GA=102